E-Learning

Broadcom shares surged to a fresh record high Monday as the chipmaker’s post-earnings rally continued.

On Friday, Nasdaq Inc's (NASDAQ:NDAQ) annual reconstitution of the Nasdaq-100 Index will become effective before the market opens on December 23. As a result, Moderna Inc. (NASDAQ:MRNA) was removed from the index. Year to date, Moderna stock has plunged over 60%, with a 52-week low-high of $35.8-$170.47, as per data from Benzinga Pro. Recently, Moderna and several other stocks witnessed a decline as Robert F. Kennedy Jr.'s, Donald Trump's nomination to lead the Department of Health and Human Ser

Prepare now for stocks to sell off at the start of 2025.

Goldman Sachs analyst Eric Sheridan initiated coverage on Grindr Inc (NYSE:GRND) with a Buy rating and a price target of $20. Grindr is an online dating platform primarily focused on serving the LGBTQ+ community with 14.6 million monthly active users (as of the third quarter of 2024) globally. In this initiation, Sheridan framed his work around three key debates for Grindr stock, including the company’s addressable market, whether it achieves a 20%+ fiscal 2024-2029 revenue CAGR, and whether it

The stainless steel market experienced a challenging year in 2024, characterized by weak demand, oversupply, and falling nickel prices.

PLBY Group, Inc. (NASDAQ:PLBY) shares rose following the announcement of an expanded partnership with Byborg Enterprises, which includes a commitment from Byborg to purchase an additional $25 million in equity. The collaboration includes finalizing a long-term, exclusive licensing agreement and signing a new securities purchase agreement with Byborg. As per the licensing deal, Byborg will license specific Playboy digital intellectual property and manage Playboy Plus, Playboy TV (both linear and

DKNG just pulled back to its historically bullish 80-day moving average

The Nasdaq climbed to a fresh high Monday as tech stocks gained ahead of an expected decision on interest rates from the Federal Reserve later this week.

On Monday, Larimar Therapeutics, Inc. (NASDAQ:LRMR) released initial data from the ongoing long-term OLE study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver in participants with Friedreich’s Ataxia. Friedreich’s Ataxia is caused by a mutation in the FXN gene, which carries the code for the frataxin protein. Frataxin is important for the normal function of mitochondria, the energy-producing parts of cells At the time of data cut

IPO Edge hosted a fireside chat on Dec. 10 at Nasdaq MarketSite with J.D. Moriarty, Chief Executive Officer of ICR Capital. The in-person interview was joined by Editor-in-Chief John Jannarone and they […]